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Diarrhea, abdominal pain, and fever are common among patients undergoing hematopoietic cell trans-
plantation (HCT), but such symptoms are also typical with foodborne infections. The burden of disease caused
by foodborne infections in patients undergoing HCT is unknown. We sought to describe bacterial foodborne
infection incidence after transplantation within a single-center population of HCT recipients. All HCT
recipients who underwent transplantation from 2001 through 2011 at the Fred Hutchinson Cancer Research
Center in Seattle, Washington were followed for 1 year after transplantation. Data were collected retro-
spectively using center databases, which include information from transplantation, on-site examinations,
outside records, and collected laboratory data. Patients were considered to have a bacterial foodborne
infection if Campylobacter jejuni/coli, Listeria monocytogenes, E. coli O157:H7, Salmonella species, Shigella
species, Vibrio species, or Yersinia species were isolated in culture within 1 year after transplantation. Non-
foodborne infections with these agents and patients with pre-existing bacterial foodborne infection (within
30 days of transplantation) were excluded from analyses. A total of 12 of 4069 (.3%) patients developed a
bacterial foodborne infection within 1 year after transplantation. Patients with infections had a median age at
transplantation of 50.5 years (interquartile range [IQR], 35 to 57), and the majority were adults 18 years of
age (9 of 12 [75%]), male gender (8 of 12 [67%]) and had allogeneic transplantation (8 of 12 [67%]). Infectious
episodes occurred at an incidence rate of 1.0 per 100,000 patient-days (95% conﬁdence interval, .5 to 1.7) and
at a median of 50.5 days after transplantation (IQR, 26 to 58.5). The most frequent pathogen detected was
C. jejuni/coli (5 of 12 [42%]) followed by Yersinia (3 of 12 [25%]), although Salmonella (2 of 12 [17%]) and Listeria
(2 of 12 [17%]) showed equal frequencies; no cases of Shigella, Vibrio, or E. coli O157:H7 were detected. Most
patients were diagnosed via stool (8 of 12 [67%]), fewer through blood (2 of 12 [17%]), 1 via both stool and
blood simultaneously, and 1 through urine. Mortality due to bacterial foodborne infection was not observed
during follow-up. Our large single-center study indicates that common bacterial foodborne infections were a
rare complication after HCT, and the few cases that did occur resolved without complications. These data
provide important baseline incidence for future studies evaluating dietary interventions for HCT patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immunocompromised patients are known to be vul-
nerable to foodborne pathogens [1-6]. Hematopoietic cell
transplantation (HCT) recipients have multiple factors that
increase risk for foodborne infections, including profound
deﬁcits in innate and adaptive immunity and disruption of
gastrointestinal mucosa from transplantation-associated
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ease (GVHD). Although such alterations provide the ideal
milieu for microbial invasion/dissemination, many patients
have additional risk factors for bacterial infections, such as
transfusion-associated iron overload, enteric acid suppres-
sion, and gastrointestinal microbiota perturbations from
antibiotic use [7-10]. Furthermore, diagnosis and treatment
may be delayed, as symptoms of foodborne infections,
notably diarrhea and fever, are nearly universal amongst HCT
recipients [11,12].
Most transplantation centers follow guidelines and
implement speciﬁc dietary strategies to reduce the risk of
exposure to foodborne pathogens. Particular emphasis has
been placed on restricting the consumption of foods more
likely to harbor high-risk bacteria by using various low-
microbial diets [13]. However, these commonly applied
guidelines have not been evaluated in randomized pro-
spective clinical trials [13,14]. Credence for such recom-
mendations is further stunted by a lack of studies addressing
the burden of bacterial foodborne infections in HCT re-
cipients [3,15]. More recent data suggest that restrictive
nutritional strategies intended to prevent the consumption
of pathogenic organisms may, in fact, increase the risk of
infection [16].
We set out to determine the burden of common bacterial
foodborne infections in a large comprehensive HCT center.
Through retrospective chart review, we aimed to describe
the incidence of bacterial foodborne pathogens within our
HCT patient population during the ﬁrst year after trans-
plantation and to assess associated morbidity and mortality.
These data are important for determining incidence of bac-
terial foodborne infections and providing a baseline for
future studies evaluating nutritional strategies in this high-
risk population.
MATERIALS AND METHODS
Study Design/Participant Eligibility
All HCT recipients who underwent an autologous or allogeneic HCT at
the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington
between January 1, 2001 and December 31, 2011 were eligible for inclusion
in this retrospective cohort. Patients with evidence of bacterial foodborne
infection 30 days before transplantation were excluded. All study activities
were approved by the FHCRC institutional review board, and all participants
provided written informed consent according to the principles of the
Declaration of Helsinki.
Data Collection
Retrospective data were retrieved from a prospectively collected data-
base of patients undergoing HCT at the FHCRC. Pre- and post-
transplantation demographic and outcome data were available from clin-
ical databases and medical records. Clinical and laboratory data after
discharge from the center were also available in long-term follow-up
databases.
Nutrition, Transplantation Procedures, and Infection Prophylaxis
Patients undergoing transplantation were encouraged to follow an
“immunosuppressed patient” diet [13] until 3 months after transplantation
(autologous recipients) or until cessation of immunosuppressive drugs
(allogeneic recipients). Before transplantation, all patients and caregivers
participated in a food safety training course that educated patients not only
onwhat foods to avoid, but also on proper preparation, cleaning, and storage
of foods and food products. Nutritional serviceswere available for all patients
to assist with questions regarding recommendations, to address post-
transplantationdietary issues, and toassure andpromoteadequatenutrition.
HCT conditioning and GVHD prophylaxis/treatment were performed
according to current standardization within the center [17]. Patients who
were neutropenic received prophylactic antibacterial therapy with either
oral levoﬂoxacin or intravenous ceftazidime. Post-transplantation patients
received antiviral prophylaxis with low-dose acyclovir [18] and all patients
underwent cytomegalovirus screening and preemptive therapy [19,20];
fungal and Pneumocystis jirovercii prophylaxes were also routine. To preventlate encapsulated bacterial infections in patients who developed chronic
GVHD, long-term prophylaxis with trimethoprim-sulfamethoxazole, either
daily or 3 times weekly, along with daily penicillin VK, was administered to
those with previous splenectomies.
Bacterial cultures from blood, stool, and other sites were conducted at
the discretion of the primary team, as center-based standard practice doc-
uments did not recommend routine testing for foodborne pathogens during
initial episodes of diarrhea. All specimens submitted for stool culture
were screened for the presence of Salmonella species (spp), Shigella spp,
Campylobacter jejuni/coli, Yersinia spp, Escherichia coli O157:H7, Vibrio spp,
Aeromonas spp and Plesiomonas. The following culture media were used:
Hektoen Enteric (HE), blood (Trypticase soy agar with 5% sheep blood),
MacConkey, MacConkey-Sorbitol, Yersinia selective and Campy CVA (cefo-
perazone, vancomycin, and amphotericin B) agars. All specimens were also
inoculated into selenite broth and subcultured to HE agar after 12 to 18
hours of incubation. Microbial identiﬁcation of potential stool pathogens
present was performed using a combination of microbiological methods,
including biochemical identiﬁcation methods (eg, VITEK 2 GN ID [Gram-
negative identiﬁcation] card [bioMérieux, Durham, NC]), as well as agglu-
tinating sera for Salmonella and Shigella spp.Deﬁnitions and Statistical Analysis
All patient events were reviewed up to 1 year after transplantation for
bacterial foodborne infections. An infectious event was deﬁned as detection
ofC. jejuni/coli, Listeriamonocytogenes,E. coliO157:H7, Salmonella spp, Shigella
spp, Vibrio spp, or Yersinia spp from any clinical site (excluding the lung) from
day 1 to day 365 after transplantation. Site of detection for all bacterial
foodborne infections was deﬁned as the site of ﬁrst positive culture. Cultures
epidemiologically linked to a non-foodborne exposure (eg, zoonotic) and
Campylobacter spp whose primary transmission is not epidemiologically
established as foodborne, such as C. curvus and C. ureolyticus, were excluded
from analyses [21]; nonspeciated cases were included and noted as such.
In this study, an attributable cause of deathwas deﬁnedwhen deathwas
documented as a direct result of the bacterial foodborne infection. Infections
in patients who survived beyond 30 days, without recurrence, were
considered resolved. All bacterial, viral, and fungal infections were identiﬁed
as concomitant if they were documented within 7 days of foodborne
event. The timing and severity of GVHD were reviewed and all episodes
were graded according to standard criteria [22]. Neutropenia during bac-
terial foodborne infection was deﬁned as an absolute neutrophil count of
<500 mm cells/mm3 within 2 days of infectious event.
Time at risk for bacterial foodborne infection was considered from the
ﬁrst day after transplantation until the bacterial foodborne event or occur-
rence of any of the following censoring events: lost to follow-up, death,
retransplantation, or 365 days. For patients with multiple transplantation
events, the at-risk periodwas considered only after the ﬁrst transplantation;
the at-risk period of patients who underwent a planned tandem trans-
plantation began after the second transplantation.
Incidence rates of bacterial foodborne infection were estimated by
dividing the number of incident cases developed in cohort subjects by the
number of post-transplantation at risk patient-days contributed by the
overall cohort; 95% conﬁdence intervals (CI) were estimated based on a
Poisson distribution. Incidence rates were also stratiﬁed by age (pediatric/
adult), with those <18 years of age considered pediatric HCT recipients.RESULTS
Of the 4074 patients who underwent HCT at the FHCRC
during the 2001 to 2011 study period, 5 were excluded from
the primary analysis because of a pre-existing foodborne
event (3 Yersinia spp, 1 C. jejuni, and 1 Salmonella spp). Among
the remaining HCT recipients, a total of 12 of 4069 (.3%) of
patients developed a post-transplantation bacterial food-
borne infection; none experienced multiple events. Patients
with these infections had a median age at transplantation of
50.5 years (interquartile range [IQR], 35 to 57) and were
primarily adults (9 of 12 [75%]) and male gender (8 of 12
[67%]) (Table 1). Themajority of infections also occurred after
allogeneic (8 of 12 [67%]) rather than autologous trans-
plantation, although cumulative incidence estimates were
similar between the 2 transplantation types (8 of 2540 [.3%]
among allogeneic versus 4 of 1529 [.3%] among autologous).
Clinical circumstances surrounding the foodborne infectious
event can be found in Table 1.
Table 1
Case Demographics and Clinical Characteristics (n ¼ 12)
Patient Demographics Foodborne Illness Clinical Characteristics
Case No. Gender/Age* Disease/HCT
Type
Conditioning Regimen GVHD Prophylaxis Organism Primary Site/Days
after HCT
Hospitalizedy Gut
GVHD
Concomitant
Infectionsz
Neutropenicx Antibacterial Regimen
at Time of Diagnosisk
1 M/35 MM/Auto Melphalan None Yersinia, NOS Feces/4 No No None Yes None
2 M/67 MM/Auto Melphalan None C. jejuni/coli Feces/6 No No None Yes Levoﬂoxacin{
3 F/46 AML/Allo BU, CY CSP, MTX Yersinia, NOS Urine/15 No No None Yes Levoﬂoxacin
4 M/57 ML/Auto CY, etoposide, I-131 None Yersinia, NOS Feces/15 Yes No CoNS; C. difﬁcile No Clindamycin
Vancomycin
Imipenem#
5 M/60 RA/Allo TREO, FLU, TBI (200 Gy) MTX, TAC C. jejuni/coli Feces/19 Yes Yes RSV/Rhinovirus No None
6 F/55 AMM/Allo BU, CY, ATG CSP, MTX, TAC Listeria monocytogenes Blood/46 No Yes None No Dapsone
7 F/4 CIMMDIS/Allo FLU, TBI (400 Gy) CSP, MMF C. jejuni Feces/55 Yes Yes Parainﬂuenza 3;
Rhinovirus; C. difﬁcile
No TMP-S
8 M/68 MDS/Allo FLU, TBI (300 Gy) CSP, MMF C. jejuni Feces/71 Yes No None No Dapsone, TMP-S**
9 M/55 MYLFI/Allo BU, CY MTX, TAC Campylobacter, NOS Feces/74 No No None No TMP-S
10 M/45 RAEB/Allo BU, CY MTX, TAC Listeria monocytogenes Blood/135 Yes Yes None Yesyy Dapsone
11 F/17 CML/Allo BU, CY CSP, MTX Salmonella, NOS Feces/175 Yes Yes C. difﬁcile No Dapsone, cephalexin
12 M/3 NBL/Auto Melphalan, etoposide, CARBO None Salmonella, NOS Blood & Feces / 351 Yes No None Unk TMP-S
M indicates male; MM, multiple myeloma; Auto, autologous transplantation; NOS, not otherwise speciﬁed; F, female; AML, acute myeloid leukemia; Allo, allogeneic transplantation; BU, busulfan; CY, cyclophosphamide; CSP,
cyclosporine; MTX, methotrexate; ML, malignant lymphoma, follicular, NOS; I-131, monoclonal antibody I-131 infusion; CoNS, coagulase negative Staphyloccocus; RA, refractory anemia, NOS; TREO, treosulfan; FLU, ﬂudarabine;
TBI, total body irradiation; TAC, tacrolimus; RSV, respiratory syncytial virus; AMM, agnogenic myeloid metaplasia; ATG, antithymocyte globulin; CML, chronic myeloid leukemia; CIMMDIS, immune deﬁciency disorder; MDS,
myelodysplastic syndrome; MMF, mycophenolate mofetil; TMP-S, trimethoprim-sulfamethoxazole; MYLFI, myeloﬁbrosis; RAEB, refractory anemia with excess blasts; NBL, neuroblastoma; CARBO, carboplatin; Unk, unknown.
* Age at time of HCT.
y Hospitalized during the course of foodborne infection.
z Documented within 7 days of foodborne infection diagnosis.
x Absolute neutrophil count <500 mm cells/mm3 within 2 days of foodborne infection diagnosis.
k Antibiotics at time of diagnosis, not those used for treatment.
{ Levoﬂoxacin started 12 hours before diagnosis.
# Multiple antibiotics changed throughout presentation.
** On low-dose trimethoprim-sulfamethoxazole during desensitization protocol at time of diagnosis.
yy Presented with neutropenia during acute episode.
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Figure 1. Frequency of common bacterial foodborne infections among HCT
patients per year of infection (n ¼ 12).
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study period at a median of 50.5 days after transplantation
(IQR, 26 to 58.5). The incidence rate of bacterial foodborne
infection was 1.0 per 100,000 patient-days (95% CI, .5 to 1.7)
for all patients, .8 (95% CI, .4 to 1.5) for adults, and 2.2 (95% CI,
.5 to 6.4) for pediatric patients. There were no apparent
associations between incidence and calendar year of trans-
plantation (Figure 1). Themost frequently detected pathogen
was C. jejuni/coli (5 of 12 [42%]), followed by Yersinia spp (3 of
12 [25%]) and equal distributions of Salmonella and Listeria
spp (2 of 12 [17%], respectively); no Shigella spp, Vibrio spp, or
E. coli O157:H7 were detected. Diagnoses were made in most
patients through stool culture (8 of 12 [67%]), whereas a
smaller proportionwere ﬁrst positive through blood cultures
(2 of 12 [17%]); 1 patient was positive simultaneously at both
sites (blood and stool), and another was ﬁrst positive in the
urine (Table 1).
Four cases had 1 or more concomitant infectious event,
including the following: Clostridium difﬁcile infection (3 of 12
[25%]), rhinovirus upper respiratory infection (2 of 12 [17%]),
and single events of parainﬂuenza (type 3) upper respiratory
infection and coagulase-negative Staphylococcus bacteremia.
Of the 8 cases in allogeneic HCT recipients, 5 (62%) were
diagnosed with gut GVHD; 4 had GVHD onset before the
bacterial foodborne infection diagnosis and 1 after. Among
the 11 cases with absolute neutrophil counts within 2 days
of infection, 4 (36%) were found to be neutropenic. Nearly
one half (5 of 12 [42%]) of cases were admitted for treatment
of their infection and/or for symptom management. No
death was found to be attributable or associated with bac-
terial foodborne infection during follow-up, and no patients
developed septic shock or required admission to intensive
care.DISCUSSION
In this retrospective cohort study,we sought to describe the
incidence of bacterial foodborne pathogens after HCT. Inci-
dence rates in the ﬁrst year after transplantation were very
low, with just 12 cases identiﬁed over an 11-year period.
Overall,Campylobacter sppwere themost frequently identiﬁed
pathogens, followed by Yersinia spp, Salmonella spp, and
L. monocytogenes. No events, even those with documented
bacteremia, were associated with major complications or
mortality in this high-risk population.Foodborne illness remains an important cause of mor-
bidity and mortality in the United States. The Centers
for Disease Control and Prevention estimates that 1 in 6
Americans will develop a foodborne infection each year [23]
and themost common of thesemicrobial agents are expected
to cause greater than 9 million illnesses and over 50,000
hospitalizations in the United States annually [24]. Given
underreporting, limitations to current diagnostic methods,
and emerging pathogens, rates are likely an underestimate of
the true burden of these infections [24,25].
Bacterial foodborne events in our HCT cohort were
infrequent, with approximately 1 event per 100,000 patient-
days. Comparing rates observed in our cohort with other
populations is difﬁcult, particularly when considering the
multiple risks associated with transplantation, including
immunosuppression, mucosal injury, and the higher fre-
quency of testing and health care engagement. Estimating
the general population’s rate of those foodborne illnesses
described in this study using the Foodborne Diseases Active
Surveillance Network data from 2001 to 2012 [26] and
extrapolating incidence rates to 100,000 patient-days sug-
gests that our HCT recipients experienced a rate approxi-
mately 10-fold that of the general population (1.0 in HCT
versus .1 in the general population). However, it should be
noted that these rough estimates do not account for signiﬁ-
cant underreporting in the general population [24], and may,
therefore, overestimate rate differences.
These data must also be taken in context, particularly
when considering factors known to modify infection risk in
our patient population, such as the routine use of prophy-
lactic antibiotics, which would be expected to provide a level
of protection against foodborne pathogens during the post-
transplantation period. Alterations in oral intake that occur
after HCT may further limit exposure, particularly among
those who receive total parenteral or peripheral nutrition
[27]. Because unregulated foodborne exposures in outpatient
environments likely make up the majority of foodborne risk,
and hospital-based bacterial foodborne infectious events are
rarely observed [28,29], expanded inpatient time would also
be expected to limit risk in these patients. Standardized food
safety education and nutritional support are also likely to
decrease exposure.
Concerns for increased susceptibility for infection have
led most programs to limit exposure to foodborne pathogens
through use of a low-microbial diet, which aims to prevent
consumption of these organisms by restricting certain
higher-risk foods. Despite implementation of low-microbial
diets across US transplantation centers [13], empirical evi-
dence supporting such recommendations is lacking [30].
Although this study cannot directly address the value of our
center’s “immunosuppressed” diet, the safety and efﬁcacy of
such low-microbial diets during HCT have been questioned
by other studies [31,32], with 1 transplantation center even
noting an increased risk of infection with the use of their
neutropenic diet [32]. Further evaluation of low-microbial
diets in HCT is complicated by the variety of dietary re-
strictions and decisions regarding timing of diet imple-
mentation across centers [30,33].
While the small number of documented events could be
interpreted as evidence of our “immunosuppressed patient”
diet’s effectiveness, it is also important to note that bacterial
foodborne illnesses did occur in this cohort, regardless of our
center’s dietary restrictions. Infectious events occurred even
during periods of neutropenia. Case reports in similar pop-
ulations and 1 cohort study of nontyphoidal Salmonella spp
N.M. Boyle et al. / Biol Blood Marrow Transplant 20 (2014) 1841e18681860from a large transplantation center [2,3,34,35] also suggest
that these ﬁndings are not likely isolated to our center.
The foodborne bacteria evaluated in this study are not
considered normal ﬂora and have been epidemiologically
deﬁned as foodborne pathogens, and as such, can serve as a
proxy for assessing risk of foodborne exposures in future
studies. It is important to note that although HCT dietary
recommendations are organized to prevent exposure to
these foodborne pathogens, such recommendations also aim
to prevent exposure to other organisms that might occur
through improper processing or food preparation practices
[36,37]. Any studies addressing dietary recommendations in
this population will need to evaluate how these changes
affect C. difﬁcile, E. coli (non-0157:H7), Staphylococcus aureus,
and other infections that are not exclusively foodborne.
As with all retrospective studies, our data were limited by
available records and reporting. Dietary compliance was not
evaluated in this study, so it is unknown if the observed
events resulted from failures of dietary guidelines or from
nonadherence. Stool cultures were not standardized and
were dependent on the clinician directing care, so it is
possible that we underestimated the true incidence. Direct
associations with speciﬁc foods or exposures could not be
addressed in this study, and these infections may not have
been acquired through foodborne pathways. Finally, this is a
single-center study, which may limit the generalizability
to other centers. Regardless, this study is the largest to date
that addresses the incidence of these pathogens in this
population.
In conclusion, common bacterial foodborne infections
were infrequently observed after HCTat our center, and these
pathogens were not associated with signiﬁcant morbidity or
mortality. These results raise additional questions about low-
microbial dietary recommendations in HCT and indicate a
need for additional studies to determine the value of such
practices. These data provide important baseline incidence
for future studies addressing dietary interventions among
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Biomarkersa b s t r a c t
Five candidateplasmabiomarkers (suppressionof tumorogenesis 2 [ST2], regenerating islet-derived-3a [REG3a],
elaﬁn, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Ra]) were measured at
speciﬁc timepoints after cyclophosphamide/ﬂudarabine-basednonmyeloablative allotransplantation (NMAT) in
patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients
were analyzed at days þ7, þ14, þ21, and þ30. At a median follow-up of 358 days, 17 patients had experienced
aGVHD with a median time to onset at day þ36. Risk of aGVHD was associated with elevated plasma ST2 con-
centrations at dayþ7 (c-statistic¼ .72, P¼ .03), dayþ14 (c-statistic¼ .74, P¼ .02), and dayþ21 (c-statistic¼ .75,
P ¼ .02); elevated plasma REG3a concentrations at dayþ14 (c-statistic¼ .73, P ¼ .03), dayþ21 (c-statistic ¼ .76,
P¼ .01), and dayþ30 (c-statistic¼ .73, P¼ .03); and elevated elaﬁn at dayþ14 (c-statistic¼ .71, P¼ .04). Plasma
concentrations of TNFR1 and sIL2Ra were not associated with aGVHD risk at any of the time points studied.
This study identiﬁed ST2, REG3a, and elaﬁn as prognostic biomarkers to evaluate risk of aGVHD after
cyclophosphamide/ﬂudarabine-based NMAT. These results need to be conﬁrmed in an independent validation
cohort.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) continues to be
a major contributor to early transplant-related mortality
after allogeneic hematopoietic cell transplantation. There is
no reliable way to determine before the onset of symptoms
who will suffer complications. To date, the choice of
candidate biomarkers for aGVHD has been guided by
studies performed in groups of patients who received
myeloablative full or reduced-intensity conditioning. We
previously demonstrated that a biomarker panel consisting
of IL-2 receptor-alpha (IL2Ra), tumor necrosis factor
receptor-1 (TNFR1), IL-8, and hepatocyte growth factor
correlated with clinical diagnosis of aGVHD as well as sur-
vival, independent of clinical grade severity. A panel of 6
biomarkers predicted treatment response and survival after
aGVHD [1,2]. Recently, the suppression of tumorogenesis 2
(ST2) was identiﬁed as a novel marker useful in predicting
glucocorticoid-resistant aGVHD and nonrelapse mortality
(NRM) [3].Nonmyeloablative allotransplantation (NMAT) condi-
tioning extends allotransplant options to older individuals
who may be at higher risk for aGVHD on the basis of age;
NMAT, a minimally intense RIC is associated with low
incidences of early transplant-related complications and
mortality. Cyclophosphamide (Cy) and ﬂudarabine (Flu)
based NMATenables engraftment in recipients of related and
unrelated HLA-matched grafts without mucositis and/or
sinusoidal obstructive syndrome [4,5]. The validation of
biomarkers across a variety of settings is critical before
attempting to integrate their use in clinical practice. We
conducted a study to test the ability of plasma levels of 5
individual biomarkers at speciﬁc time points to serve as
prognostic markers for aGVHD among patients undergoing
Cy/Flu-based NMAT.METHODS
Patient Population
Thirty-four patients with hematological malignancies who underwent
Cy/Flu-based NMAT at Indiana University between 2008 and 2012 were
included in the study, which was approved by the Indiana University
institutional review board. Disease status at transplant was categorized
according to the American Society of Blood and Marrow Transplantation
criteria [6].
Patients received mobilized peripheral blood hematopoietic cells from
matched relatedormatchedunrelateddonors.GVHDprophylaxis formatched
unrelated donor recipients consisted of cyclosporine A  mycophenolate
mofetil or basiliximab (NCT00975975) or a combination of tacrolimus and
sirolimus. Matched related recipients received a combination of cyclosporine
A  mycophenolate mofetil or basiliximab. Patients were followed prospec-
tively until death or for a median of 358 days (range, 182 to 1381 days) and
